SYK: the growth is real; the recovery premium must be earned

The 60-second read

Five things to know

1. Guidance falls despite organic growth. Full-year organic growth moves to 6.5–7.0% from 8.3–9.3%; the quarter grew 7.7%.
2. Adjusted strength masks a wider reported-profit gap. Adjusted operating income is $1.706B versus $1.034B GAAP; the impairment is the largest quarterly add-back.
3. Peripheral Vascular needs an economic recovery. The goodwill charge reflects lower forecast cash flows, supply constraints and a longer recovery period.
4. Cash generation supports capital allocation, with limits. Nine-month FCF is $2.698B before acquisitions; buybacks and dividends consume $2.012B.
5. Robotics optionality is not booked revenue. The October CMR agreement proposes a $400M preferred-equity investment and U.S. distribution rights, subject to closing conditions.

Three scenarios, one probability-weighted number

Swipe the table sideways on a phone. 12-month ex-dividend scenario prices for November 9, 2027. Current fair value remains $330; current scenario anchors are $240/$330/$420.

Signposts: what would change our mind

Thresholds are our tests, not management promises. The next packet should grade them against the same definitions and dates.

Price and expectations

The reference is the November 9, 2026 close of $325.73, not an intraday November 10 quote. The October 29 release followed the close; the next-session close changed -6.4% against October 29. That price movement captures the whole information bundle and wider market conditions. It cannot be causally assigned to the goodwill charge alone. Subsequent trading has already changed the valuation opportunity, which is why a falling price immediately after earnings is not itself a buy thesis.

At the reference price, reported September common shares produce approximately $124.0B of equity value. Adding $11.659B of net debt gives $135.7B of enterprise value. Our forward valuation instead uses 385M shares, slightly above the quarter-end count, and therefore a larger modeled market capitalization. Both denominators are labeled. A weighted-average diluted earnings denominator, a point-in-time common share count and a forward model assumption answer different questions; swapping them silently would create spurious precision.

The company has a durable medical-technology franchise, but durability does not guarantee that every valuation premium is justified. Around 21.9 times the midpoint of reduced 2026 adjusted EPS guidance, investors are paying for continuing growth and recovery. Our HOLD balances that franchise against the narrow gap to estimated value. The return opportunity becomes more attractive if price supplies a discount or if evidence supports higher sustainable cash flow; neither condition should be assumed from a favorable long-term demographic story alone.

The quarter and the guidance reset

Sales were $6.520B, up 7.7% both reported and organically. Currency and net acquisition/divestiture effects rounded to zero at the consolidated level. Organic growth removes those effects; it is not another revenue amount to add to reported sales. Management attributes growth primarily to higher unit volume. This is a healthy demand result in absolute terms, but the chief executive said performance fell short of internal expectations. A business can grow and still disappoint the growth path embedded in its prior outlook.

GAAP operating income fell 8.9% to $1.034B and GAAP diluted EPS fell 11.7% to $1.96. Adjusted operating income rose to $1.706B, adjusted margin reached 26.2%, and adjusted EPS rose 10.3% to $3.52. The two stories coexist because the company excludes acquisition-related, amortization, restructuring, impairment, regulatory and tax items from adjusted measures. We use both views. Reported accounts measure the full recognized costs; adjusted numbers help examine underlying operations but are not automatically the cash available to owners.

The July 30 release guided 2026 organic growth to 8.3–9.3% and adjusted EPS to $14.95–15.10. The October release reduced those ranges to 6.5–7.0% and $14.80–14.90. The organic-growth midpoint fell 2.05 percentage points; the EPS midpoint fell $0.175, about 1.2%. That difference suggests expense discipline and earnings resilience are softening the sales disappointment. It does not establish that all missing sales were deferred and will return next year. Guidance remains forward looking and the issuer does not reconcile its future adjusted EPS to GAAP because specified items cannot be predicted reliably.

Where the growth came from

MedSurg and Neurotechnology generated $3.664B of sales, with 9.1% organic growth. Orthopaedics generated $2.856B with 5.9% organic growth. Their segment operating profits were $1.052B and $891M. Those figures exclude corporate and specified unallocated items; they are not two pieces that simply sum to consolidated GAAP operating profit. The filing reconciles $1.943B of segment profit through corporate cost and adjustments to the $1.034B GAAP total. Segment margins are useful for relative operating direction, provided the reconciliation stays visible.

Endoscopy sales rose 13.9% and Ortho Tech rose 15.8%, while knees rose only 1.1% and hips declined 1.0%. The growth mix therefore matters more than a single consolidated percentage. Instruments, Medical, Vascular and Trauma and Extremities supply additional diversification. We do not invent installed robot counts, procedure growth or product profitability when the quarterly release supplies sales instead. High product growth can reflect different capital purchasing cycles and comparison bases; it should not be projected unchanged across every business.

Stryker reorganized reporting in the first quarter of 2026. Ortho Tech combines Orthopaedic Instruments and Other Orthopaedics, while Neuro Cranial and enabling technologies moved into Instruments. The current release recasts its comparative periods. We use the recast Q3 comparison for segment analysis and preserve contemporaneous total-company historical statements separately. Comparing an unrecast old Instruments revenue line with the new category would wrongly attribute a reporting change to operating growth. The Spinal Implants disposal also affects comparisons, so organic growth is the cleaner current demand check.

The profit bridge and acquisition economics

The $672M gap between adjusted and GAAP operating income is economically important. The quarter adds back $293M of impairment, $175M of purchased-intangible amortization, $153M of structural and other special charges, $17M of acquisition/integration cost, $6M for medical-device regulations and $32M of regulatory/legal matters, offset by a $4M recall benefit. The result is $1.706B adjusted operating income. Purchased-intangible amortization is noncash in the current period, but its asset arose from past capital deployment. Excluding it helps compare operations; it does not make acquisition capital free.

The goodwill impairment relates to the Peripheral Vascular reporting unit. The filing says the reduced cash-flow forecast reflects near-term operational and supply constraints and a longer expected period to achieve anticipated growth and market recovery. That is an economic signal beyond a noncash accounting entry. It is not proof that all of Inari is impaired or that AVS has failed. Inari, acquired in February 2025 for $4.810B net of acquired cash, and AVS sit within this broader business. The reporting-unit disclosure does not isolate the charge to one named acquired company.

Below operating income, Q3 interest expense was $143M and other income $106M, giving pretax earnings of $997M. Tax expense of $244M leaves $753M of net income. The 24.5% GAAP effective tax rate exceeds the 16.0% adjusted rate in part because the goodwill impairment is not deductible. Adjusted net income is $1.357B. The nine-month accounts also include a $158M reversal of 2025 tariffs in GAAP operating income, removed in the adjusted reconciliation. We keep that favorable item separate; assuming it recurs would overstate underlying annual improvement.

Earnings quality and cash conversion

Nine-month operating cash flow was $3.303B; subtracting $605M of property and equipment purchases gives $2.698B of free cash flow. That is 97.3% of GAAP net income and 71.3% of adjusted net income. Neither ratio should be read without the denominator: GAAP contains noncash impairment and adjusted profit removes costs that may still consume cash. Quarter-only FCF, computed from successive cumulative filings, was $1.224B. Seasonal timing matters, so multiplying this quarter by four would be less informative than the $4.573B trailing total.

Inventory absorbed $468M of cash over nine months, while receivables released $320M. At September 30, inventories were $5.747B and receivables $3.693B. Simple end-balance days are about 231 inventory days and 52 receivable days using quarterly cost of sales and revenue with 91.25 days. These are diagnostics, not company-reported turnover statistics: acquisitions, product mix, seasonality and point-in-time balances can distort them. Inventory should be judged with supply availability and future sales, not assumed to be either waste or guaranteed future revenue.

Share-based compensation was $208M over nine months and $67M in the quarter, modest relative to sales but still a cost of rewarding employees. Our normalized earnings and cash models retain recurring compensation. There is no material minority-interest subtraction in the current net-income presentation. Tax, special charges and acquisition accounting deserve more attention than an invented minority leakage story. Disclosure controls were reported effective. That supports the reporting process, but it does not guarantee estimates, future profitability or immunity from another operational incident.

Balance sheet and capital allocation

Cash was $3.271B and reported debt was $14.930B, including $754M of current maturities. Net debt is therefore $11.659B. Operating lease liabilities of $503M are excluded from this financial-net-debt definition, and the model retains operating lease expense in margins. The distinction avoids combining a lease-capitalized enterprise value with an unadjusted operating-profit measure. Net debt is about $30.28 per modeled share. It is a financial claim that enterprise-value methods must subtract before allocating the business value to common owners.

Nine-month dividends of $1.012B and repurchases of $1.000B consumed $2.012B, leaving $686M of FCF before acquisitions and other financing/investing movements. Acquisitions used $481M net of acquired cash. This arithmetic shows that distributions are meaningful without implying the cash balance should equal a simple residual: debt payments, currencies, tax withholding and other items also move cash. The third-quarter repurchase reduced point-in-time shares, but future buybacks remain discretionary. An authorization is permission to spend, not a promise of accretion at any price.

AVS cost $434M net cash plus up to $400M of milestone payments, initially valued at $271M. Its lithotripsy platform was still under development, with acquired in-process research and development subject to regulatory risk. Separately, the October CMR Surgical agreement calls for approximately $400M in preferred equity, exclusive U.S. distribution rights for Versius and an exclusive option to acquire the remaining equity. Closing was expected in Q4 subject to approvals and conditions. We do not book hypothetical CMR revenue or a completed acquisition, and we do not value the option as if its future purchase price were zero.

Three routes to present value

Our DCF estimates present value as of November 9, 2026 using complete annual periods for 2027–2031, discounted one through five years. This is a simplified annual timing convention, not a precise partial-year model. Revenue rises from $28.5B to $38.5B; normalized operating margin expands from 26% to 28%. The model retains recurring compensation and normal operating costs, but excludes purchased-intangible amortization and episodic special charges. Consequently the depreciation add-back is only 1.8% of revenue; we do not add purchased amortization a second time. Capital spending is 3% and working-capital investment 15% of incremental sales, starting from an assumed $27B 2026 base.

We apply an 18% operating tax rate, an 8.5% discount rate and 3% terminal growth. The resulting enterprise value is $125.63B; after subtracting $11.659B net debt and dividing by 385M forward shares, value is $296.03 per share. About 79.3% of enterprise value lies in the terminal component. That is a warning about sensitivity, not a validation of the point estimate. The implied recovery is substantive: modeled 2027 cash flow exceeds recent trailing FCF. Investors need better conversion and growth, not merely the absence of a new impairment.

The earnings route assumes $16.25 normalized 2027 EPS and 23 times earnings, giving $373.75. It is an equity method, so debt is not subtracted again. The enterprise-earnings route uses $28.5B revenue × 26% normalized margin × 19 times EBIT, less $11.659B net debt, divided by 385M shares: $335.41. These are explicit Charged Alpha assumptions, not management guidance or peer facts. Weighting DCF 50%, earnings 30% and EV/EBIT 20% produces $327.22, rounded to a $330 base value. The cross-checks share assumptions and should not be mistaken for three independent forecasts.

At $325.73, the stock pays 21.9 times current-year adjusted guidance midpoint and 20.0 times our normalized 2027 EPS. Modeled enterprise value is about 18.5 times our 2027 EBIT. The price therefore already grants a meaningful operating recovery. High uncertainty calls for a 15% discount to the $330 base before a potential BUY, roughly $281, with the thesis intact. Our current bear/base/bull equity anchors of $240/$330/$420 have 30%/50%/20% probabilities and a $321 weighted present value. Separately, we calculate November 9, 2027 ex-dividend prices by compounding those anchors at an assumed 9% equity return and subtracting $3.52 assumed dividends. This gives $258.08/$356.18/$454.28 and a $346.37 weighted future price. The equity hurdle exceeds the 8.5% enterprise discount rate because equity bears the debt claim; it is an explicit author assumption, not a quoted market rate. The dividend assumption holds the reported quarterly $0.88 rate constant, aggregates cash at year end and assumes no reinvestment. These conditional roll-forwards require unchanged scenario valuations and assumptions; they are not predictions of inevitable convergence. Current fair value and the $281 potential entry threshold do not change.

Compared with Wall Street

FMP records Stifel at $325 on November 2, BMO Capital at $309 and RBC Capital at $375 on October 30. These are dated provider records of broker targets, not original research reports independently obtained by this packet. The dispersion is useful: there is no single Wall Street view. Our $330 present-value estimate is close to Stifel and above BMO, but below RBC. Broker targets generally have their own forward horizons and assumptions, so comparison is directional rather than a claim of identical valuation methods.

The aggregate target snapshot is $354.47, with a $359 median and a $309–407 range. Because the feed does not identify the effective date of every aggregate contributor, we do not call that number a purely post-earnings consensus. Ratings counts include one strong buy, 35 buys and 16 holds, with no sells. Optimistic ratings can coexist with target cuts and a reduced outlook. We prioritize the disclosed cash-flow assumptions over treating the number of positive opinions as a probability that the stock will rise.

Execution and management scorecard

Management earns credit for sustaining volume growth and adjusted margin expansion through a difficult year. It also deserves scrutiny for a large organic-growth guidance reduction and an acquisition reporting unit whose cash-flow expectations fell enough to trigger impairment. The correct score is mixed. Neither a strong franchise nor a noncash characterization should exempt capital allocation from evaluation. Future updates need evidence of supply normalization, better product breadth and cash generation that validates the price paid for acquired assets.

The March cyber incident materially disrupted first-quarter operations. The April 9 amendment reported restoration of operations while the investigation remained ongoing. The Q3 filing still flags uncertainty about the incident’s effects, and nine-month gross-margin commentary notes first-quarter idle-production costs. Restoration is not the same as a quantified end to every cost or risk. We do not attribute the entire Q3 growth shortfall or goodwill impairment to the cyber event without issuer evidence, and we do not treat the residual risk language as proof of a new attack.

Five questions frame the next management discussion: what portion of weak growth reflects procedure demand versus supply; when will Peripheral Vascular meet its revised cash expectations; how much capital is required beyond the initial AVS payment; what milestones justify exercising the CMR option; and how much cash remains after dividends, acquisitions and buybacks? Answers should distinguish observed results from aspirations. The 2025 annual auditor was Ernst & Young LLP. Listed common stock is the covered security, with no ADS conversion in our per-share arithmetic.

Risks and the strongest alternative case

The bull case deserves a serious hearing. Hospitals and clinicians need innovation, procedure demand can compound, and a broad sales organization can distribute complementary technologies more efficiently than a small standalone company. Endoscopy and Ortho Tech demonstrate that growth has not vanished. A normalized operating margin above the current adjusted level, combined with better inventory conversion, could generate substantially more cash. Our bull case allows a premium for that outcome. It does not require assuming every acquired project reaches its maximum addressable market.

The bear case is equally specific. Supply problems and slower procedural growth could delay recovery while acquired research, sales infrastructure and financing costs continue. Repeated special charges can become an ordinary feature of an acquisition-led business. A lower valuation multiple would then amplify modest earnings disappointment. Product recalls, litigation, reimbursement pressure, competition and tariffs can affect cash and demand. The impairment is noncash today, but persistent reductions in expected cash flows would directly weaken the valuation rather than merely change presentation.

The quarterly Section 13(r) disclosure concerns a Russian subsidiary filing three notifications with the FSB under the OFAC General License described by the issuer. These licensing/notification activities were free of charge and the company attributed no gross revenue or net profit to those activities. Stryker says it expects to continue only while authorized by that license, a successor or another OFAC authorization. This disclosure requirement can apply whether activities are prohibited or sanctionable. We make no inference of unlawful conduct, payments to sanctioned parties, or zero Russian product revenue from the absence of revenue attributable to the notification activities themselves.

Dated checkpoints

The next expected major evidence window is the fourth-quarter release in January 2027 and the annual filing that follows; this timing is an expectation, not an issuer-confirmed event date. We will test the revised EPS range, underlying sales growth, cash conversion and any update to the impairment outlook. The proposed CMR transaction has a stated Q4 closing expectation subject to conditions. Closing alone would not prove that future distributions or the acquisition option create value; commercial adoption and capital requirements still matter.

A more constructive call requires either a meaningful price discount with operating evidence intact or a supported increase in durable cash generation. Our approximate $281 entry threshold is 15% below base value, not a limit order or promise of downside protection. A further guidance cut, persistent inventory build or another material impairment would require revisiting the model even at a lower price. Conversely, sustained organic growth with stronger cash conversion could make the current caution too conservative. The decision framework is designed to change with evidence rather than defend a static target.

Data, definitions and source trail

Amounts are U.S. dollars in millions unless a per-share, percentage or share-count unit is explicitly shown. The nine-quarter history runs from Q3 2024 to Q3 2026. Each GAAP operating-income row was checked against the issuer earnings release and the filing’s inline facts; fourth-quarter filing checks use annual less nine-month income where required. We did not import a provider operating-income history without reconciliation. The unusually low Q4 2024 GAAP operating income of $581M is retained, reflecting that quarter’s reported costs rather than an adjusted substitute.

Quarterly operating cash flow and capital spending are computed from differences between cumulative statements. The three annual cash histories come from SEC filings. Free cash flow here means operating cash less property-and-equipment purchases and is before acquisitions, dividends and repurchases. DCF uses a separate normalized unlevered cash-flow definition with tax and reinvestment assumptions made explicit. That modeled cash flow is neither reported GAAP income nor issuer guidance. Positive values do not establish that all cash can be distributed immediately.

Historical expense presentation changed as impairment costs became a separate line and segment organization changed. The source dataset retains the original release reconciliation and distinguishes missing separate-line data from zero economic cost. Current comparative segment data are recast by the issuer. An unreported metric is not invented to make a chart look complete. The source archive retains release tables, filings, SEC facts and dated FMP market snapshots; source hashes allow independent review to identify the exact evidence used.

No verified prior Charged Alpha packet scorecard was incorporated into this candidate, so this page makes no historical forecasting-performance claim. Its dated signposts establish the baseline for the next review. Price history and broker records are market data, while scenario probabilities, discount rates, future margins and valuation multiples are author judgments. They are deliberately identified separately. Readers should focus on the assumptions that change the investment conclusion, not on false precision in a rounded fair-value estimate.

• companyfacts.json
• submissions.json
• quote.json
• profile.json
• historical-price-eod_full.json
• grades.json
• grades-consensus.json
• price-target-consensus.json
• price-target-news.json
• analyst-estimates.json
• earnings.json
• 0000310764-26-000061_syk-20260930.htm
• 0000310764-26-000050_syk-20260630.htm
• 0000310764-26-000031_syk-20260331.htm
• 0000310764-26-000010_syk-20251231.htm
• 0000310764-25-000129_syk-20250930.htm
• 0000310764-25-000107_syk-20250630.htm
• 0000310764-25-000075_syk-20250331.htm
• 0000310764-25-000023_syk-20241231.htm
• 0000310764-24-000115_syk-20240930.htm
• 0000310764-24-000098_syk-20240630.htm
• 0000310764-24-000064_syk-20240331.htm
• 0000310764-24-000024_syk-20231231.htm
• 2026-10-29_release.htm
• 2026-07-30_release.htm
• 2026-04-30_release.htm
• 2026-01-29_release.htm
• 2025-10-30_release.htm
• 2025-07-31_release.htm
• 2025-05-01_release.htm
• 2025-01-28_release.htm
• 2024-10-29_release.htm
• cyber_april9_8ka.htm